COVID-19 markers test using a microfluidics technology developed by Optofluidic Bioassay

SOPHIA-ANTIPOLIS, France – April 28, 2020 | According to Optofluidic Bioassay, COVID-19 antibody testing which is portable, fast, cheap and highly precise could be possible with a microfluidic device invented by the company. Optofluidic Bioassay was founded in 2015 as a spin-off of the University of Michigan. The company was identified as relevant microfluidics company[…]

Patent analysis is a powerful tool for startup identification and valuation in the field of Microfluidics

SOPHIA-ANTIPOLIS, France – March 12, 2020 | Microfluidics is a very dynamic technological field involving numerous technologies and having numerous applications (e.g. Healthcare, Biotech., the Environment, Microelectronics, etc.), and this domain sees the arrival of numerous startups every year. “Because of their small size and technological diversity, these young companies are hard to identify by[…]

Abcellera’s patent involved in its collaboration with Gilead in infectious disease

SOPHIA-ANTIPOLIS, France – June 14, 2019: Abcellera’s patent involved in its collaboration with Gilead in infectious disease. AbCellera has announced a partnership with Gilead to discover antibodies for infectious disease. AbCellera will apply its expertise in single-cell screening of natural immune sources to generate rich panels of antibody candidates for evaluation by Gilead. Gilead is[…]

Applied Materials may enter the field of next-generation sequencing

SOPHIA-ANTIPOLIS, France – May 6, 2019: Nanopore sequencing is one of the next-generation sequencing (NGS) technologies believed to be capable of revolutionizing DNA analysis. Nanopore sequencing is performed using an electrical detection method, which generally includes transporting a sample through the nanopore, which is immersed in a conducting fluid, and applying electric potential across the[…]